Autoren

Dr. Manja Epping

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More

Judith Krens

Partner

Read More
Autoren

Dr. Manja Epping

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More

Judith Krens

Partner

Read More

29. April 2020 |

Everything biologic and biosimilar in-house counsel need to know about COVID-19

In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.

In this session we focussed on critical developments impacting biologic and biosimilar companies, including:

  • regulatory responses and challenges in the US and Europe
  • changes in patent office policies and proceedings
  • developments in the court systems, and
  • dealing with contractual and supply chain issues.
Call To Action Arrow Image

Newsletter-Anmeldung

Wählen Sie aus unserem Angebot Ihre Interessen aus!

Jetzt abonnieren
Jetzt abonnieren

Related Insights

centrifuge-machine
Life Sciences & Healthcare

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27. Juli 2020
QUICK READ

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Termination, force majeure and frustration – international perspectives on the life sciences sector

17. April 2020
QUICK READ

von mehreren Autoren

Klicken Sie hier für Details
scientist-with-molecule-models
Life Sciences & Healthcare

Biosimilars – Clearing the way for launch

30. September 2019
QUICK READ

von mehreren Autoren

Klicken Sie hier für Details

Events

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.